Trastuzumab, Bevacizumab with Paclitaxel for HER2-positive Gastric Cancer in a Second-line Therapy

Launched by KANGBUK SAMSUNG HOSPITAL · Dec 5, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a combination of three medications—trastuzumab, bevacizumab, and paclitaxel—as a second-line treatment for patients with HER2-positive advanced gastric cancer. This means that the trial is looking for ways to help patients whose cancer has not improved after their first treatment, which may have included trastuzumab or similar drugs. The goal is to see if this new combination of treatments can help manage their cancer more effectively.

To be eligible for this trial, participants must be adults aged 19 or older with HER2-positive advanced gastric cancer, which is confirmed through specific laboratory tests. They should have had one prior treatment for their cancer but still have measurable signs of the disease. Participants will be monitored closely during the trial to ensure their safety and to see how well the treatment works. It's important to know that certain health conditions or recent treatments may exclude someone from participating, so potential participants should discuss their medical history with their healthcare provider to see if this trial may be a good option for them.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. HER2-positive advanced gastric cancer
• • Defined as IHC 2+, which is IHC 3+ or SISH + (or FISH) evaluated by laboratory tests. (SISH positivity is defined as the ratio of the HER2 gene copy number to the CEP17 signal ≥ 2.0)
• • or significant overexpression of HER2 protein on target proteomic analysis (multiple reaction monitoring)
• • 2. Patients who have progressed in response to one systemic anticancer therapy for advanced gastric cancer
• • 3. Patients who are willing and able to write a written consent form for this trial.
• • 4. Patients aged 19 years or older at the time of signing the subject consent form.
• • 5. Patients with measurable or evaluable lesions according to RECIST 1.1.
• • 6. ECOG activity status 0, 1 or 2
• • 7. as patients with adequate organ function
• • Absolute neutrophil (ANC) ≥1.0 x 109/L, platelet ≥100 x 109/L, hemoglobin ≥9 g/dL, serum creatinine ≤1.5 x ULN, total bilirubin ≤3.0 mg on laboratory tests within 2 weeks before starting treatment /dL, AST/ALT ≤5 x ULN
• • Echocardiogram EF ≥55% or MUGA scan ≥50%
• Exclusion Criteria:
• • 1. Patients who have received chemotherapy, radiation therapy, immunotherapy or targeted therapy for gastric cancer within the past 2 weeks.
• • 2. Patients who have experienced Grade 3-4 gastrointestinal bleeding within 3 months
• • 3. Patients who have experienced an arteriovascular embolism event, including but not limited to myocardial infarction, transient ischemic attack, cerebrovascular disorder, or unstable angina within 6 months
• • 4. Ongoing or active infection, symptomatic congestive heart failure, unstable angina, symptomatic or poorly controlled cardiac arrhythmias, uncontrolled thrombotic or hemorrhagic disorders, or any other serious medical disorder not controlled in the investigator's judgment patient with
• • 5. Patients with a history of gastrointestinal perforation or fistula within 6 months.
• • 6. Concomitant diagnosis of cancer in another site or history of active malignant tumor within the past 3 years
• • Excluding fully cured basal cell carcinoma and thyroid cancer, in situ cervical cancer

Trial Officials